Can Chronic Lupron Use Cause Neuropathy?
Yes, chronic Lupron (leuprolide acetate) use can cause peripheral neuropathy, though this is a rare adverse event documented in postmarketing surveillance rather than a common or expected side effect.
Evidence from FDA Drug Label
The FDA label for Lupron explicitly lists peripheral neuropathy as a postmarketing adverse reaction 1. The label states: "Nervous/Psychiatric System: Mood swings, including depression; suicidal ideation and attempt; convulsion, peripheral neuropathy, paralysis" among reactions identified during post-approval use 1.
Importantly, the FDA notes that "because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure" 1. This means:
- Peripheral neuropathy has been reported in association with Lupron use
- The exact incidence rate is unknown
- A definitive causal relationship cannot be firmly established from postmarketing data alone
- The reaction appears to be uncommon given it's in the postmarketing section rather than clinical trial adverse events
Clinical Context
The mechanism by which Lupron might cause neuropathy is not well-established. Unlike chemotherapeutic agents where drug-induced peripheral neuropathy (DIPN) is common and well-characterized 2, 3, GnRH agonists like leuprolide are not traditionally recognized as neurotoxic medications in the standard literature on drug-induced neuropathy 4, 5.
Interestingly, one animal study actually suggested leuprolide acetate may have neuroprotective properties in spinal cord injury, showing structural and functional recovery 6. This contrasts with the postmarketing reports of neuropathy, highlighting the complexity of this drug's neurological effects.
Clinical Approach
When evaluating a patient on chronic Lupron therapy presenting with neuropathy symptoms:
- Consider Lupron as a possible but uncommon cause based on FDA postmarketing data
- Rule out more common etiologies first: diabetes, vitamin B12 deficiency, alcohol use, other medications, hereditary neuropathies
- Review all concurrent medications for more established neurotoxic agents
- Document the temporal relationship between Lupron initiation and symptom onset
- Consider risk-benefit analysis of continuing versus discontinuing Lupron, particularly given the serious indications for which it's prescribed
The neuropathy association exists but remains poorly characterized in terms of frequency, severity, and reversibility upon drug discontinuation.